en · de · es · fr · pt
aod-9604-notes.peptides3626.com › Faq › Identity And Molecular Context — Worked Examples

Identity And Molecular Context — Worked Examples

By Editorial Desk · published 2025-11-20 · last reviewed 2025-12-28 · Faq

A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2025-12-28 and is reviewed periodically as new material appears.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Regulatory and Analytical Context

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Related pages on this site

Background and Development History

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Further detail

==== Base-specific cleavage/MALDI-TOF ==== A recently described method by Ehrich et al. further takes advantage of bisulfite-conversions by adding a base-specific cleavage step to enhance the information gained from the nucleotide changes. By first using in vitro transcription of the region of interest into RNA (by adding an RNA polymerase promoter site to the PCR primer in the initial amplification), RNase A can be used to cleave the RNA transcript at base-specific sites. As RNase A cleaves RNA specifically at cytosine and uracil ribonucleotides, base-specificity is achieved by adding incorporating cleavage-resistant dTTP when cytosine-specific (C-specific) cleavage is desired, and incorporating dCTP when uracil-specific (U-specific) cleavage is desired. The cleaved fragments can then be analyzed by MALDI-TOF. Bisulfite treatment results in either introduction/removal of cleavage sites by C-to-U conversions or shift in fragment mass by G-to-A conversions in the amplified reverse strand. C-specific cleavage will cut specifically at all methylated CpG sites. By analyzing the sizes of the resulting fragments, it is possible to determine the specific pattern of DNA methylation of CpG sites within the region, rather than determining the extent of methylation of the region as a whole. This method demonstrated efficacy for high-throughput screening, allowing for interrogation of numerous CpG sites in multiple tissues in a cost-efficient manner.

Amines, alkyl and aryl alike, are organized into three subcategories (see table) based on the number of carbon atoms adjacent to the nitrogen (how many hydrogen atoms of the ammonia molecule are replaced by hydrocarbon groups): Primary (1°) amines—Primary amines arise when one of three hydrogen atoms in ammonia is replaced by an alkyl or aromatic group. Important primary alkyl amines include methylamine, most amino acids, and the buffering agent tris, while primary aromatic amines include aniline. Secondary (2°) amines—Secondary amines have two organic substituents (alkyl, aryl or both) bound to the nitrogen together with one hydrogen. Important representatives include dimethylamine, while an example of an aromatic amine would be diphenylamine. Tertiary (3°) amines—In tertiary amines, nitrogen has three organic substituents. Examples include trimethylamine, which has a distinctively fishy smell, and EDTA. A fourth subcategory is determined by the connectivity of the substituents attached to the nitrogen:

In January 1985, the sixth generation Familia/323 was fully renewed. It was available as a hatchback (with three or five doors) or four-door saloon only for the first year; wagon and cabriolet models were added in November 1985 and March 1986 respectively. The wagon was commonly sold as a light van in Japan, but for the first time it was also available as a passenger-oriented wagon model in the Japanese domestic market. In November 1986, cumulative production of Familias (excluding vans and pickups) reached five million units; at the time, Mazda was building about 40,000 Familia/323s per month. In January 1987 a personal coupé version with its own bodywork, the Étude, was added. In February 1987 the Familia range underwent a light facelift that included replacing the old E engines with the more modern B series. In some markets, such as Indonesia, the E engine continued to be installed after the facelift. This generation of the Familia/323 was also available in a version with a turbocharged DOHC engine, with either front- or four-wheel drive, producing 140 PS (103 kW). The 4WD version (sold in either a lightweight GT or fully optioned GT-X grade) introduced in October 1985, saw some success in rally's Group A category. A limited production Japanese-only homologation special, the 4WD GT-Ae, appeared May 1988 and offered an additional ten horsepower and viscous rear limited slip differential (similar to the later BG Familia). Full time four-wheel drive was also available in more pedestrian versions like the 1.5 hatchback.

Sources: en.wikipedia.org

Supporting material

=== Recruitment and spending policy === Youth development and scouring for talent abroad is central to Wenger's recruitment policy. He relies on a network of scouts and personal contacts to find and attract talented footballers to play under him. Wenger's strategy is aided by data; for instance, the decision to sign Flamini in 2004 came about as he was looking at statistics to find an understudy to Vieira. To examine the mental state of a young footballer, he uses psychometric tests conducted by psychologist Jacques Crevoisier once every two years. Wenger prides himself on nurturing talent, saying in an interview: "I believe one of the best things about managing people is that we can influence lives in a positive way. That's basically what a manager is about. When I can do that, I am very happy". In his early managerial years, Wenger recognised the potential of football in Africa, which influenced his transfer dealings at Monaco. On the recommendation of Claude Le Roy, he signed Liberian George Weah, who later became the first African to be named FIFA World Player of the Year. Weah, while receiving his award from FIFA president João Havelange and vice-president Lennart Johansson invited Wenger up to the stage, spontaneously giving his medal to the manager, as a token of his appreciation. During his final years at Monaco, Wenger worked with Roger Mendy, a Senegalese defender regarded in 1991 as one of the ten best African footballers by France Football, and Nigerian Victor Ikpeba, a forward who earnt the accolade of African Player of the Year.

== Impact on health == The primary nutritional benefits of nixtamalization arise from the alkaline processing involved. The processing renders the protein more digestible, allowing tryptophan to be absorbed by humans. Humans can convert tryptophan into niacin, thus helping to prevent pellagra. Other measures of protein quality are also improved. It was originally thought that the anti-pellagra action stems from increased availability of niacin (compared to a hemicellulose-bound form called "niacytin"), but multiple experiments have disproven this theory. Secondary benefits can arise from the grain's absorption of minerals from the alkali used or from the vessels used in preparation. These effects can increase calcium (by 750%, with 85% available for absorption), iron, copper, and zinc. Nixtamalization significantly deactivates mycotoxins which are putative carcinogens. Aflatoxins are reduced by 90–94%. Fumonisins are reduced by 82%.

== External links == Mercaptans (or Thiols) at The Periodic Table of Videos (University of Nottingham) Applications, Properties, and Synthesis of ω-Functionalized n-Alkanethiols and Disulfides – the Building Blocks of Self-Assembled Monolayers by D. Witt, R. Klajn, P. Barski, B.A. Grzybowski at Northwestern University. Mercaptan, by The Columbia Electronic Encyclopedia What is Mercaptan? Archived 2008-12-20 at the Wayback Machine, by Columbia Gas of Pennsylvania and Maryland. What Is the Worst Smelling Chemical? Archived 2011-06-06 at the Wayback Machine, by About Chemistry.

== Antiphage defense in Bacteria == Bacterial ubiquitination is an evolutionarily conserved protein modification pathway that plays a role in bacterial antiviral defense. It exhibits structural and functional parallels to eukaryotic ubiquitination systems and contributes to bacterial defense against Bacteriophage. Recent reviews highlight the conservation and similarity of bacterial and eukaryotic innate immunity mechanisms. In one study, it was demonstrated that during phage infection, a bacterial system conjugates a Ubl protein to the phage's central tail fiber, a component essential for tail assembly and host recognition. This modification leads to the production of defective phage particles with impaired infectivity, thereby protecting the bacterial population from phage proliferation. Another study revealed that a bacterial operon associated with phage defense encodes a complete ubiquitination pathway. Structural analyses of the bacterial E1–E2–Ubl complex showed significant similarities to canonical eukaryotic ubiquitination machinery, suggesting that the ubiquitination pathway may have originated in bacteria. In all organisms, innate immune pathways sense infection and rapidly activate potent immune responses while avoiding inappropriate activation (autoimmunity). In humans, the innate immune receptor cyclic GMP–AMP synthase (cGAS) detects viral infection to produce the nucleotide second messenger cyclic GMP–AMP (cGAMP), which initiates stimulator of interferon genes (STING)-dependent antiviral signaling.

Sources: en.wikipedia.org

Supporting material

== Fragile states == The Fragile States Index 2019, compiled by the NGO, Fund for Peace, ranked Thailand 77th in the world for fragility (178=least fragile; 1=most fragile). Finland topped the ranking; Yemen was at the bottom. Other ASEAN nations were ranked: Singapore, 162; Brunei, 124; Malaysia, 119; Vietnam, 109; Indonesia, 93; Laos, 62; Cambodia, 54; Philippines, 50; Myanmar, 22.

Furthermore, a narrow wound, less than 1 mm wide can be allowed to heal by secondary intention (autonomous re-epithelialisation). III. Paramedian forehead flap The paramedian forehead flap is the premier autologous skin graft for the reconstruction of a nose, by replacing any of the aesthetic nasal subunits, especially regarding the problems of different tissue thickness and skin color. The forehead flap is an axial skin flap based upon the supraorbital artery (an ophthalmic artery branch) and the supratrochlear artery (an ophthalmic artery terminus), which can be thinned to the subdermal plexus in order to enhance the functional and aesthetic outcome of the nose. Restricted length is a practical application limit of the paramedian forehead flap, especially when the patient has a low frontal hairline. In such a patient, a small portion of scalp skin can be included to the flap, but it does have a different skin texture and does continue growing hair; such mismatching is avoided with the transverse emplacement of the flap along the hairline; yet that portion of the skin flap is random, and so risks a greater incidence of necrosis. The paramedian forehead flap has two disadvantages, one operational and one aesthetic: Operationally, the reconstruction of a nose with a paramedian forehead flap is a two-stage surgical procedure, which might a problem for the patient whose health (surgical suitability) includes significant, secondary medical risks. Nonetheless, the second stage of the nasal reconstruction can be performed with the patient under local anaesthesia.

=== OpenTag === DASH7 Mode 2 developers benefit from the open-source firmware library called OpenTag, which provides developers with a "C"-based environment in which to develop DASH7 applications quickly. So in addition to DASH7 (ISO 18000-7) being an open source, ISO standard, OpenTag is an open-source stack that is quite unlike other wireless sensor networking (e.g. ZigBee) and active RFID (e.g. proprietary) options elsewhere in the marketplace today. Even though OpenTag is an open-source project, people may not be able to use it free of charge. As of August 2015, there is no evidence to suggest that OpenTag bears a royalty, although current versions of OpenTag license Archived 2013-12-31 at the Wayback Machine do include a provision permitting RAND licensing.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network